Some points from the presentation.
Significant deterioration of QoL (QLQ-C30-B23) observed in the
placebo group at 6 months. No deterioration with efti (Figure 6).
• Efti significantly increased CD8 T cells compared to placebo
(Figure 7). (Note: Blood samples were taken 2 weeks after last dosing and prior to
next dosing, showing the minimal residual effect.)
• Increase in pre-dose CD8 T cells is significantly correlated to
increased overall survival (Figure 8).
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-74
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.005(1.49%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.0¢ | 33.0¢ | $1.220M | 3.642M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 57289 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 52306 | 3 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |